Guangdong New South Artemisinin Pharmaceutical

Guangdong New South Artemisinin Pharmaceutical is a specialized pharmaceutical company focused on the development and production of artemisinin-based antimalarial treatments. The company is most notable for its flagship product, Artequick, a fourth-generation artemisinin-based combination therapy (ACT) consisting of artemisinin and piperaquine phosphate. Developed in collaboration with the Guangzhou University of Chinese Medicine, the company's products are central to malaria elimination strategies globally, particularly in Africa and Southeast Asia. It operates a large-scale manufacturing facility in Meizhou, Guangdong, which is GMP-certified for the extraction and formulation of artemisinin derivatives. The company is a subsidiary of the Guangdong New South Group and continues to lead clinical research into rapid malaria eradication.